Treatment‐related mortality · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in treatment‐related mortality compared with standard induction therapies (low certainty).
1 finding from 1 review
Mortality due to tumour lysis syndrome · children with haematological malignancy at risk of tumour lysis syndrome
1 finding from 1 review
Overall survival (reported as mortality) · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).
1 finding from 1 review
Mortality due to tumour lysis syndrome · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: urate oxidase may leads to lower mortality due to tumour lysis syndrome ( compared with allopurinol (low certainty).
1 finding from 1 review
Overall survival (reported as mortality) · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in overall survival (reported as mortality) compared with no further treatment (low certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment‐related mortality ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Has died · children with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in overall mortality (Reported as number of participants who died) compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Overall survival with intravenous platinum (i.e. mortality/number of participants deceased) · children with cancer treated with platinum‐based therapy
Sodium thiosulfate showed no clear difference in overall survival with intravenous platinum (i.e. mortality/number of… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Event‐free survival · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower event‐free survival (reported as relapse, progressive disease,… compared with standard therapy (moderate certainty).
1 finding from 1 review